Death from thyroid cancer of follicular cell origin
- 31 December 2000
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 191 (6), 600-606
- https://doi.org/10.1016/s1072-7515(00)00731-6
Abstract
Although patients with differentiated thyroid cancer (DTC) of follicular cell origin usually have an excellent prognosis, some patients die from progressive tumor. Numerous postoperative criteria have been used to predict prognosis in patients with DTC. The purpose of this investigation was to determine whether the TNM and metastases, age, completeness of resection, invasion, size (MACIS) classifications predicted survival time and why patients died from DTC. The extent of initial treatment and causes of death were also evaluated in these patients who died from thyroid cancer. Between 1965 and 1995, 102 of 1,224 patients with DTC treated at the University of California at San Francisco (UCSF) and UCSF/Mount Zion Medical Centers died from DTC. Risk factors including age at diagnosis, gender, histologic characteristics, TNM and MACIS classifications, the intervals among initial treatment, recurrence, and death, and the initial and subsequent treatments were documented in these 102 patients. Among the 102 patients who died of DTC 50% were men and 50% were women. The mean age of patients with DTC at diagnosis was 58 years at recurrence, 62 and 65 years at death. Thirty percent of these patients initially had unilateral thyroid operations and 70% had a bilateral operation. Tumors at presentation ranged from 0.6 to 13.0 cm (mean 4.4 cm); 46% of patients presented with late-stage tumors (TNM stage III, IV; MACIS score > 8). At presentation 46% of the patients had locally recurrent disease or regional metastases and 18% had distant metastases. Patients with persistent disease had a significantly shorter survival time than those with recurrent disease (p < 0.001). Both TNM and MACIS classifications were good predictors of survival time. Reoperations were performed in 51% of papillary, 26% of follicular, and 67% of Hürthle cell thyroid cancer patients. Fifty percent of patients with papillary thyroid cancer, 50% of patients with Hürthle cell thyroid cancer, and 11% of patients with follicular cell thyroid cancer died of locally advanced disease. As expected, patients with local or regional recurrence and those with TNM stage I or MACIS score < 6 survived longer than patients with distant metastasis and TNM stage III or IV, MACIS score > 6, but some patients thought to be at low risk (TNM stage I; MACIS < 6) also died from thyroid cancer.Keywords
This publication has 16 references indexed in Scilit:
- Pathological Tumor-Node-Metastasis (pTNM) Staging for Papillary and Follicular Thyroid Carcinomas: A Retrospective Analysis of 700 PatientsJournal of Clinical Endocrinology & Metabolism, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Changing concepts in the pathogenesis and management of thyroid carcinomaCA: A Cancer Journal for Clinicians, 1996
- Differentiated carcinoma of the thyroid with extrathyroidal extensionThe American Journal of Surgery, 1995
- Morbidity and mortality in follicular thyroid cancerJournal of Clinical Endocrinology & Metabolism, 1995
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerAmerican Journal Of Medicine, 1994
- The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progressionEndocrine Pathology, 1993
- Manual for Staging of Cancer, 3rd editionAmerican Journal of Clinical Oncology, 1988
- Total thyroidectomyAnnals of Surgery, 1982
- A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative groupEuropean Journal of Cancer (1965), 1979